Progestins for symptomatic endometriosis: a critical analysis of the evidence.
about
Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgeryLevonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgeryClinical practice. EndometriosisRecent advances in the understanding of endometriosis: the role of inflammatory mediators in disease pathogenesis and treatmentPathophysiology and Immune Dysfunction in EndometriosisToday's treatments: medical, surgical and in partnership.Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis.Role of estrogen receptor-β in endometriosisAnxiety and depression in patients with endometriosis: impact and management challenges.Optimal management of chronic cyclical pelvic pain: an evidence-based and pragmatic approachReevaluating response and failure of medical treatment of endometriosis: a systematic review.17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosisOral contraceptives and risk of endometriosis: a systematic review and meta-analysis.Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis.Endometriosis: current concepts and therapy.Recurrence of endometriosis and its control.Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus.Glucoregulatory function in adult rhesus macaques (Macaca mulatta) undergoing treatment with medroxyprogesterone acetate for endometriosis.Emerging drugs for endometriosis.Aromatase inhibition for refractory endometriosis-related chronic pelvic pain.Novel targets for the treatment of endometriosis.Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications.Advances in the management of endometriosis: an update for clinicians.Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis.Emerging drugs in endometriosis.Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial.Long-term use of progestogens--effects on endometriosis, adenomyosis and myomas.The non-human primate model of endometriosis: research and implications for fecundity.The effect of surgery for symptomatic endometriosis: the other side of the story.Medical treatment for rectovaginal endometriosis: what is the evidence?Aberrant DNA methylation status of endometriosis: epigenetics as the pathogenesis, biomarker and therapeutic target.Endometriosis: an update on management.Progestin therapy in endometriosis.Progesterone resistance in endometriosis: origins, consequences and interventions.NSAID resistance in dysmenorrhea: epidemiology, causes, and treatment.Synthetic Steroid Hormones Regulated Cell Proliferation Through MicroRNA-34a-5p in Human Ovarian Endometrioma.Cytokines regulate matrix metalloproteinases in human uterine endometrial fibroblast cells through a mechanism that does not involve increases in extracellular matrix metalloproteinase inducer.Pain associated with endometriosis: therapeutic options.
P2860
Q24201678-A1FF55CD-A940-4178-BB4D-AFF7FC896936Q24244299-98978A79-FF22-4AF5-AFB1-A433F3F6D8F0Q24625416-37DA20B7-0267-41CB-B59E-B08BC2148602Q26767444-ECEC76CF-FC16-4093-8DC6-8E3D7F700856Q26801594-56798CFE-73B3-49A8-B35A-7251E130A2A2Q33546043-1A074DA2-051E-46AF-8C92-DB6088F3CC00Q33574256-AE8D9766-EEC8-4E3F-80A4-6C73CEDFDCE6Q33667641-80454181-15AE-481A-B0BF-75864BA8CB09Q33713984-DE4E1F7C-08FF-4394-A610-39227B87BDE0Q33769215-19C45C4A-330B-4020-B5A1-A5F096D02171Q33862947-9D8C0615-124B-45EA-8970-3A103D158BE7Q34095248-1DC4DB07-E25E-4D8E-9312-73D5F74CC825Q34137437-9DC6FCA6-3898-4D32-80DB-F9183BF1400EQ34321877-8080F57B-99FE-4EB8-8C03-61B37650C990Q34418066-8DA1CCE6-3E17-426E-AFF0-DAE3EA34CDC5Q34775795-7FE48054-DD7A-4A15-B277-98A3DF8FE238Q34783617-5FF40009-C722-4D72-99D4-A245145A5777Q34961059-8AFE0300-56FA-4C09-BF95-56BF4926ECA7Q35551056-19888EDE-8CFB-4E58-BD0F-1B8C3655F62CQ35587342-CED4C74C-14AA-4FEE-AADF-7B53E9D24286Q35779301-7A8CC46D-7669-4B41-AB55-7E1F83F02C2FQ35838301-AB8251BE-2A2F-439E-8002-01A2961C06DEQ35911132-8362EC7C-8F44-409E-9D9D-FB4CF40CCDC6Q36261408-14900A23-3B1F-4A0A-9EC6-CDA4CA2F082EQ36310331-A428CE00-9DA6-44DD-9929-DFED787434DCQ36521148-9D5A7B2F-F412-4F4A-B72F-C05A11146DA1Q36580603-6DD621F2-DDC4-4974-8493-47B9DB935BA9Q36839274-5F52EE09-FD1C-4603-9B14-0143F743FBC7Q36974414-EE6BEA55-BEB0-4AF9-A679-4C9CA7F08A90Q37348033-E23D6358-5824-4C19-B794-85784C761962Q37366253-EB59BD31-A493-4A03-A456-2D6A52F9D50BQ37539459-097A4E62-2F67-49B9-A3AC-7D32A23FFE6CQ37886274-434D2260-9522-4BB6-B738-E56328874CC1Q38103587-BAD1C197-08B8-4DD5-BA6F-C8667DFDAF83Q38590182-E91A17D0-4663-40C3-9BF8-4E286B251824Q39250801-9354810D-8120-421F-95F7-1E51F2B584D1Q40049589-02CAA017-DA2B-4414-A34C-EEA14D70366DQ40050612-FE66ECF5-6247-46F3-896E-4A7E68D39419Q40243432-1D15E9E3-74F4-432D-9A71-56D3A8A57926Q40311549-D9509CED-18C2-42E0-9073-9545126CDBFE
P2860
Progestins for symptomatic endometriosis: a critical analysis of the evidence.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Progestins for symptomatic endometriosis: a critical analysis of the evidence.
@en
Progestins for symptomatic endometriosis: a critical analysis of the evidence.
@nl
type
label
Progestins for symptomatic endometriosis: a critical analysis of the evidence.
@en
Progestins for symptomatic endometriosis: a critical analysis of the evidence.
@nl
prefLabel
Progestins for symptomatic endometriosis: a critical analysis of the evidence.
@en
Progestins for symptomatic endometriosis: a critical analysis of the evidence.
@nl
P1476
Progestins for symptomatic endometriosis: a critical analysis of the evidence
@en
P2093
P G Crosignani
P304
P356
10.1016/S0015-0282(97)00193-3
P407
P577
1997-09-01T00:00:00Z